NZ749202A - Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto - Google Patents
Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoInfo
- Publication number
- NZ749202A NZ749202A NZ749202A NZ74920217A NZ749202A NZ 749202 A NZ749202 A NZ 749202A NZ 749202 A NZ749202 A NZ 749202A NZ 74920217 A NZ74920217 A NZ 74920217A NZ 749202 A NZ749202 A NZ 749202A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- phenoxy
- pyridinyl
- methyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346293P | 2016-06-06 | 2016-06-06 | |
| PCT/US2017/035867 WO2017214002A1 (en) | 2016-06-06 | 2017-06-05 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ749202A true NZ749202A (en) | 2022-07-01 |
Family
ID=59067920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ749202A NZ749202A (en) | 2016-06-06 | 2017-06-05 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20190284200A1 (enExample) |
| EP (1) | EP3464292B8 (enExample) |
| JP (3) | JP6771246B2 (enExample) |
| KR (2) | KR20190026731A (enExample) |
| CN (1) | CN109563103B (enExample) |
| AR (1) | AR108772A1 (enExample) |
| AU (2) | AU2017278102B2 (enExample) |
| CA (1) | CA3026024C (enExample) |
| CL (1) | CL2018003451A1 (enExample) |
| CO (1) | CO2019000041A2 (enExample) |
| CR (1) | CR20180595A (enExample) |
| DK (1) | DK3464292T3 (enExample) |
| EA (1) | EA201892817A1 (enExample) |
| EC (1) | ECSP19001018A (enExample) |
| ES (1) | ES2929737T3 (enExample) |
| IL (2) | IL289378B (enExample) |
| MA (2) | MA44037B1 (enExample) |
| MX (2) | MX387995B (enExample) |
| MY (1) | MY195982A (enExample) |
| NI (1) | NI201800130A (enExample) |
| NZ (1) | NZ749202A (enExample) |
| PE (1) | PE20190445A1 (enExample) |
| PH (1) | PH12018502550B1 (enExample) |
| PT (1) | PT3464292T (enExample) |
| SG (1) | SG11201810788QA (enExample) |
| TN (1) | TN2018000391A1 (enExample) |
| TW (2) | TWI752963B (enExample) |
| UA (1) | UA125120C2 (enExample) |
| WO (1) | WO2017214002A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| MD3448859T2 (ro) | 2017-03-20 | 2020-03-31 | Forma Therapeutics Inc | Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR) |
| MA51015A (fr) | 2017-12-06 | 2021-04-21 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| AU2020350763A1 (en) | 2019-09-19 | 2022-04-07 | Novo Nordisk Health Care Ag | Pyruvate kinase R (PKR) activating compositions |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| JP2023024954A (ja) * | 2021-08-09 | 2023-02-21 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ベータ－３アドレナリン作動性受容体に関連する障害の処置または予防に有用なベータ－３アドレナリン作動性受容体のモジュレーター |
| WO2023026185A1 (en) * | 2021-08-26 | 2023-03-02 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome |
| EP4413005A1 (en) * | 2021-10-06 | 2024-08-14 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
| EP4479384A1 (en) * | 2022-02-14 | 2024-12-25 | Biogen MA Inc. | Emopamil-binding protein inhibitors and uses thereof |
| CN114539103B (zh) * | 2022-03-21 | 2023-04-07 | 佳木斯黑龙农药有限公司 | 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法 |
| CN116178220A (zh) * | 2022-12-13 | 2023-05-30 | 爱斯特（成都）生物制药股份有限公司 | 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3028340C2 (de) * | 1980-07-25 | 1987-02-05 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| FR2751646B1 (fr) | 1996-07-23 | 1999-01-22 | Sanofi Sa | Phenoxypropanolamine a action antagoniste beta3-adrenergique |
| WO1998027080A1 (en) | 1996-12-19 | 1998-06-25 | Agrevo Uk Limited | Chromones useful as fungicides |
| FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| DE60033964T2 (de) * | 1999-12-17 | 2007-11-29 | Sanofi-Aventis | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung |
| DE20204129U1 (de) | 2002-03-15 | 2002-07-25 | Wella Ag, 64295 Darmstadt | Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen |
| WO2005092860A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds for the treatment of diseases |
| JP2008521805A (ja) * | 2004-11-30 | 2008-06-26 | アーテシアン セラピューティクス， インコーポレイテッド | β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物 |
| US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
| WO2008094507A2 (en) | 2007-01-26 | 2008-08-07 | Cellicon Biotechnologies, Inc. | Novel fusion compounds |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| WO2009059225A2 (en) | 2007-11-02 | 2009-05-07 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| CA2779252C (en) | 2008-10-31 | 2015-05-05 | Pain Therapeutics, Inc. | Filamin a-binding anti-inflammatory analgesic |
| CA2779261C (en) | 2008-10-31 | 2015-03-24 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| WO2010058318A1 (en) * | 2008-11-21 | 2010-05-27 | Pfizer Inc. | 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors |
| US8785634B2 (en) * | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| CN103140134B (zh) * | 2010-07-23 | 2015-07-29 | 默沙东公司 | 新吡咯烷衍生的β3肾上腺素能受体激动剂 |
| JP2012092038A (ja) | 2010-10-26 | 2012-05-17 | F Hoffmann La Roche Ag | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 |
| WO2014011917A2 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | A method of inhibiting tau phosphorylation |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| MA51015A (fr) * | 2017-12-06 | 2021-04-21 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci |
-
2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 PH PH1/2018/502550A patent/PH12018502550B1/en unknown
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/en active Active
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 CA CA3026024A patent/CA3026024C/en active Active
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 MX MX2018015124A patent/MX387995B/es unknown
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active Withdrawn
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/en not_active Ceased
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active Active
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
-
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
-
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
-
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
-
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
-
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021206809B2 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| EP3720858B1 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| WO2010059610A1 (en) | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof | |
| HK40004811A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40004811B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| BR112018075201B1 (pt) | Compostos moduladores do receptor beta-3 adrenérgico e composição farmacêutica que os compreende, seus usos e método de preparação da referida composição | |
| EA041181B1 (ru) | Модулятор бета-3-адренергического рецептора, применяемый для лечения или предотвращения связанных с данным рецептором расстройств | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40006318A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40006318B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3093282, BLACKBURN, ANTHONY C., 12633 CAMINITO ROSITASAN DIEGO, CALIFORNIA 92128, US; 3646447, TRAN, THUY-ANH, 4833 FAIRPORT WAYSAN DIEGO, CALIFORNIA 92130, US; 3646448, DO, QUYEN-QUYEN, 10414 ROSEDUST GLEN DRIVESAN DIEGO, CALIFORNIA 92127, US; 3646449, ULLMAN, BRETT, 3046 40TH STREETSAN DIEGO, CALIFORNIA 92105, US; 3682651, NAGURA, MAIKO, 3128 VIA ALICANTE, UNIT D, LA JOLLA, CA 92037, US Effective date: 20191004 |
|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |